Category: St. Jude Medical
St. Jude Medical meets Wall Street's expectations for its 1st quarter of 2014 with moderate sales growth across its product lines, but shares take a downward turn in morning trading.
Minnesota medtech titan St. Jude Medical (NYSE:STJ) lost a few points on Wall Street today after posting 1st quarter earnings a penny above analysts' consensus estimate.
Here's a look at some of the top regulatory stories for medical device companies this week.
Class I recalls: 10
Class II recalls: 183
St. Jude Medical says the FDA approved its Protégé spinal cord stimulator for treating chronic pain.
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.
MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
Medtronic's Symplicity renal denervation device for hypertension lowered blood pressure only slightly more than patients treated with drugs and a sham procedure, the company said Saturday at the American College of Cardiology's annual conference.
Medtronic (NYSE:MDT) revealed the details of a clinical trial of its Symplicity renal denervation treatment for hypertension, but said it still plans to investigate the treatment even though the study showed only meager improvements in high blood pressure compared with a sham procedure.
A small European feasibility study of the Nanostim leadless pacemaker acquired by St. Jude Medical looks good at 3 months, according to a study published in the American Heart Assn. journal Circulation.
The Nanostim leadless pacemaker acquired by St. Jude Medical (NYSE:STJ) last year appeared safe and functional after 3 months, according to results of a small study published in the American Heart Assn. journal Circulation.